Seminars in Spine Surgery
Volume 19, Issue 4 , Pages 272-279 , December 2007

An Update on the Pathophysiology of Acute Spinal Cord Injury

  • Cody M. Mann, BSc

      Affiliations

    • Department of Zoology, International Collaboration on Repair Discoveries, University of British Columbia, Vancouver, British Columbia, Canada.
    • ,
  • Brian K. Kwon, MD, PhD, FRCSC

      Affiliations

    • Combined Neurosurgical and Orthopaedic Spine Program, Department of Orthopaedics, International Collaboration on Repair Discoveries, University of British Columbia, Vancouver, British Columbia, Canada.
    • Corresponding Author InformationAddress reprint requests to Brian K. Kwon, MD, PhD, FRCSC, D6 Heather Pavilion, Vancouver General Hospital, Department of Orthopaedics, University of British Columbia, 2733 Heather Street, Vancouver, BC V5Z 3J5.

References 

  1. Norenberg MD, Smith J, Marcillo A. The pathology of human spinal cord injury: defining the problems. J Neurotrauma. 2004;21:429–440
  2. Blight AR. Cellular morphology of chronic spinal-cord injury in the cat—analysis of myelinated axons by line-sampling. Neuroscience. 1983;10:521–543
  3. Eidelberg E, Straehley D, Erspamer R, et al. Relationship between residual hindlimb-assisted locomotion and surviving axons after incomplete spinal-cord injuries. Exp Neurol. 1977;56:312–322
  4. Fehlings MG, Tator CH. The relationships among the severity of spinal-cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal-cord injury. Exp Neurol. 1995;132:220–228
  5. Koyanagi I, Tator CH, Piepmeier JM, et al. Silicone-rubber microangiography of acute spinal-cord injury in the rat. Neurosurgery. 1993;32:260–268
  6. Tator CH, Koyanagi I. Vascular mechanisms in the pathophysiology of human spinal cord injury. J Neurosurg. 1997;86:483–492
  7. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal-cord trauma with emphasis on vascular mechanisms. J Neurosurg. 1991;75:15–26
  8. Mautes AE, Weinzierl MR, Donovan F, et al. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther. 2000;80:673–687
  9. Teasell RW, Arnold JMO, Krassioukov A, et al. Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. Arch Phys Med Rehabil. 2000;81:506–516
  10. Harrop JS, Sharan AD, Vaccaro AR, et al. The cause of neurologic deterioration after acute cervical spinal cord injury. Spine. 2001;26:340–346
  11. Levi L, Wolf A, Belzberg H, et al. Hemodynamic parameters in patients with acute cervical cord trauma—description, intervention, and prediction of outcome. Neurosurgery. 1993;33:1007–1017
  12. Wrathall JR, Teng YD, Choiniere D. Amelioration of functional deficits from spinal cord trauma with systemically administered NBQX, an antagonist of non-N-methyl-D-aspartate receptors. Exp Neurol. 1996;137:119–126
  13. Li S, Mealing GA, Morley P, et al. Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J Neurosci. 1999;19:RC16
  14. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261–1276
  15. Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci. 2000;20:1190–1198
  16. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci. 1987;7:369–379
  17. Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke. 1998;29:705–718
  18. Feldblum S, Arnaud S, Simon M, et al. Efficacy of a new neuroprotective agent, Gacyclidine, in a model of rat spinal cord injury. J Neurotrauma. 2000;17:1079–1093
  19. Fairbanks CA, Schreiber KL, Brewer KL, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA. 2000;97:10584–10589
  20. Li SX, Tator CH. Action of locally administered NMDA and AMPA/kainate receptor antagonists in spinal cord injury. Neurol Res. 2000;22:171–180
  21. Agrawal SK, Fehlings MG. Role of NMDA and non-NMDA ionotropic glutamate receptors in traumatic spinal cord axonal injury. J Neurosci. 1997;17:1055–1063
  22. Haghighi SS, Johnson GC, deVergel CF, et al. Pretreatment with NMDA receptor antagonist MK801 improves neurophysiological outcome after an acute spinal cord injury. Neurol Res. 1996;18:509–515
  23. Yanase M, Sakou T, Fukuda T. Role of N-methyl-D-aspartate receptor in acute spinal cord injury. J Neurosurg. 1995;83:884–888
  24. Liu SL, Ruenes GL, Yezierski RP. NMDA and non-NMDA receptor antagonists protect against excitotoxic injury in the rat spinal cord. Brain Res. 1997;756:160–167
  25. Lammertse DP. Update on pharmaceutical trials in acute spinal cord injury. J Spinal Cord Med. 2004;27:319–325
  26. Rosenberg LJ, Teng YD, Wrathall JR. 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline reduces glial loss and acute white matter pathology after experimental spinal cord contusion. J Neurosci. 1999;19:464–475
  27. Stys PK. White matter injury mechanisms. Curr Mol Med. 2004;4:113–130
  28. Regan RF, Choi DW. Glutamate neurotoxicity in spinal-cord cell-culture. Neuroscience. 1991;43:585–591
  29. Agrawal SK, Fehlings MG. Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+,Na+-K+-ATPase, the N+-H+ exchanger, and the Na+-Ca2+ exchanger. J Neurosci. 1996;16:545–552
  30. Stys PK, Waxman SG, Ransom BR. Na+-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central-nervous-system white matter. Ann Neurol. 1991;30:375–380
  31. Stys PK, Sontheimer H, Ransom BR, et al. Noninactivating, tetrodotoxin-sensitive Na+ conductance in rat optic-nerve axons. Proc Natl Acad Sci USA. 1993;90:6976–6980
  32. Rosenberg LJ, Teng YD, Wrathall JR. Effects of the sodium channel blocker tetrodotoxin on acute white matter pathology after experimental contusive spinal cord injury. J Neurosci. 1999;19:6122–6133
  33. Teng YD, Wrathall JR. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J Neurosci. 1997;17:4359–4366
  34. Rosenberg LJ, Wrathall JR. Time course studies on the effectiveness of tetrodotoxin in reducing consequences of spinal cord contusion. J Neurosci Res. 2001;66:191–202
  35. Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg. 2001;94:245–256
  36. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol. 1998;18:667–682
  37. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res. 1998;39:1529–1542
  38. Lukacova N, Halat G, Chavko M, et al. Ischemia-reperfusion injury in the spinal cord of rabbits strongly enhances lipid peroxidation and modifies phospholipid profiles. Neurochem Res. 1996;21:869–873
  39. Basu S, Hellberg A, Ulus AT, et al. Biomarkers of free radical injury during spinal cord ischemia. FEBS Lett. 2001;508:36–38
  40. Bolanos JP, Heales SJR, Land JM, et al. Effect of peroxynitrite on the mitochondrial respiratory-chain - differential susceptibility of neurons and astrocytes in primary culture. J Neurochem. 1995;64:1965–1972
  41. Kaptanoglu E, Okutan O, Akbiyik F, et al. Correlation of injury severity and tissue Evans blue content, lipid peroxidation and clinical evaluation in acute spinal cord injury in rats. J Clin Neurosci. 2004;11:879–885
  42. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma. 2000;17:871–890
  43. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262:689–695
  44. Reynolds IJ, Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci. 1995;15:3318–3327
  45. Sakamoto A, Ohnishi ST, Ohnishi T, et al. Relationship between free-radical production and lipid-peroxidation during ischemia-reperfusion injury in the rat-brain. Brain Res. 1991;554:186–192
  46. Saunders RD, Dugan LL, Demediuk P, et al. Effects of methylprednisolone and the combination of alpha-tocopherol and selenium on arachidonic-acid metabolism and lipid-peroxidation in traumatized spinal-cord tissue. J Neurochem. 1987;49:24–31
  47. Kanter M, Coskun O, Kalayci M, et al. Neuroprotective effects of Nigella sativa on experimental spinal cord injury in rats. Hum Exp Toxicol. 2006;25:127–133
  48. Cakir E, Usul H, Peksoylu B, et al. Effects of citicoline on experimental spinal cord injury. J Clin Neurosci. 2005;12:923–926
  49. Liu DX, Bao F, Prough DS, et al. Peroxynitrite generated at the level produced by spinal cord injury induces peroxidation of membrane phospholipids in normal rat cord: reduction by a metalloporphyrin. J Neurotrauma. 2005;22:1123–1133
  50. Gul S, Celik SE, Kalayci M, et al. Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats. Surg Neurol. 2005;64:355–361
  51. Luo J, Shi RY. Diffusive oxidative stress following acute spinal cord injury in guinea pigs and its inhibition by polyethylene glycol. Neurosci Lett. 2004;359:167–170
  52. Jones TB, McDaniel EE, Popovich PG. Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des. 2005;11:1223–1236
  53. Bethea JR. Spinal cord injury-induced inflammation: a dual-edged sword. Neural Plasticity Regen. 2000;128:33–42
  54. Gris D, Marsh DR, Oatway MA, et al. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci. 2004;24:4043–4051
  55. Dusart I, Schwab ME. Secondary cell-death and the inflammatory reaction after dorsal hemisection of the rat spinal-cord. Eur J Neurosci. 1994;6:712–724
  56. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol. 1997;377:443–464
  57. Blight AR. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma. 1985;2:299–315
  58. Blight AR. Macrophages and inflammatory damage in spinal-cord injury. J Neurotrauma. 1992;9:S83–S91
  59. Blight AR. Effects of silica on the outcome from experimental spinal-injury—implication of macrophages in secondary tissue-damage. Neuroscience. 1994;60:263–273
  60. Popovich PG, Guan Z, Wei P, et al. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol. 1999;158:351–365
  61. Franzen R, Schoenen J, Leprince P, et al. Effects of macrophage transplantation in the injured adult rat spinal cord: a combined immunocytochemical and biochemical study. J Neurosci Res. 1998;51:316–327
  62. Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med. 1998;4:814–821
  63. LazarovSpiegler O, Solomon AS, ZeevBrann AB, et al. Transplantation of activated macrophages overcomes central nervous system regrowth failure. FASEB J. 1996;10:1296–1302
  64. Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. J Neurosurg Spine. 2005;3:173–181
  65. Frei K, Bodmer S, Schwerdel C, et al. Astrocyte-derived interleukin-3 as a growth-factor for microglia cells and peritoneal-macrophages. J Immunol. 1986;137:3521–3527
  66. Sawada M, Kondo N, Suzumura A, et al. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989;491:394–397
  67. Fabry Z, Fitzsimmons KM, Herlein JA, et al. Production of the cytokines interleukin 1 and 6 by murine brain microvessel endothelium and smooth muscle pericytes. J Neuroimmunol. 1993;47:23–34
  68. Pan JZ, Ni L, Sodhi A, et al. Cytokine activity contributes to induction of inflammatory cytokine mRNAs in spinal cord following contusion. J Neurosci Res. 2002;68:315–322
  69. Yune TY, Chang MJ, Kim SJ, et al. Increased production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats. J Neurotrauma. 2003;20:207–219
  70. Xu J, Fan GS, Chen SW, et al. Methylprednisolone inhibition of TNF-alpha expression and NF-kappa B activation after spinal cord injury in rats. Mol Brain Res. 1998;59:135–142
  71. Genovese T, Mazzon E, Crisafulli C, et al. Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther. 2006;316:1006–1016
  72. Bruce AJ, Boling W, Kindy MS, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 1996;2:788–794
  73. Cheng B, Christakos S, Mattson MP. Tumor necrosis factors protect neurons against metabolic excitotoxic insults and promote maintenance of calcium homeostasis. Neuron. 1994;12:139–153
  74. Barger SW, Horster D, Furukawa K, et al. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA. 1995;92:9328–9332
  75. Kim GM, Xu J, Xu JM, et al. Tumor necrosis factor receptor deletion reduces nuclear factor-kappa B activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury. J Neurosci. 2001;21:6617–6625
  76. Tonai T, Taketani Y, Ueda N, et al. Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats. J Neurochem. 1999;72:302–309
  77. Schwab JM, Brechtel K, Nguyen TD, et al. Persistent accumulation of cyclooxygenase-1 (COX-1) expressing microglia/macrophages and upregulation by endothelium following spinal cord injury. J Neuroimmunol. 2000;111:122–130
  78. Resnick DK, Graham SH, Dixon CE, et al. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma. 1998;15:1005–1013
  79. Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol. 2001;64:327–363
  80. Liu DX, Li LP, Augustus L. Prostaglandin release by spinal cord injury mediates production of hydroxyl radical, malondialdehyde and cell death: a site of the neuroprotective action of methylprednisolone. J Neurochem. 2001;77:1036–1047
  81. Hains BC, Yucra JA, Hulsebosch CE. Reduction of pathological and behavioral deficits following spinal cord contusion injury with the selective cyclooxygenase-2 inhibitor NS-398. J Neurotrauma. 2001;18:409–423
  82. Hall ED, Wolf DL. A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal-cord ischemia. J Neurosurg. 1986;64:951–961
  83. Noble LJ, Donovan F, Igarashi T, et al. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci. 2002;22:7526–7535
  84. Yong VW, Power C, Forsyth P, et al. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2:502–511
  85. Raff M. Cell suicide for beginners. Nature. 1998;396:119–122
  86. Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 1997;3:73–76
  87. Li GL, Brodin G, Farooque M, et al. Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. J Neuropathol Exp Neurol. 1996;55:280–289
  88. Springer JE, Azbill RD, Knapp PE. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med. 1999;5:943–946
  89. Emery E, Aldana P, Bunge MB, et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg. 1998;89:911–920
  90. Li M, Ona VO, Chen M, et al. Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury. Neuroscience. 2000;99:333–342
  91. Ray SK, Hogan EL, Banik NL. Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Rev. 2003;42:169–185
  92. Ozawa H, Keane RW, Marcillo AE, et al. Therapeutic strategies targeting caspase inhibition following spinal cord injury in rats. Exp Neurol. 2002;177:306–313
  93. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004;25:609–612
  94. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci. 2004;24:2182–2190
  95. Wells JEA, Hurlbert RJ, Fehlings MG, et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003;126:1628–1637
  96. Bartesaghi S, Marinovich M, Corsini E, et al. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology. 2005;26:923–928
  97. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99:2258–2263
  98. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002;99:9450–9455
  99. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101:14907–14912
  100. Kaptanoglu E, Solaroglu I, Okutan O, et al. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev. 2004;27:113–120
  101. Boran BO, Colak A, Kutlay M. Erythropoietin enhances neurological recovery after experimental spinal cord injury. Restor Neurol Neurosci. 2005;23:341–345
  102. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495–505
  103. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–125
  104. Stuve O, Youssef S, Steinman L, et al. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol. 2003;16:393–401
  105. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000;80:1095–1100
  106. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78–84
  107. Pannu R, Barbosa E, Singh AK, et al. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res. 2005;79:340–350

PII: S1040-7383(07)00109-8

doi: 10.1053/j.semss.2007.09.009

Seminars in Spine Surgery
Volume 19, Issue 4 , Pages 272-279 , December 2007

Article Tools